This large sector covers the production and sale of consumer goods, as well as various consumer services including electronic commerce and health care. Since 1996, Baring Vostok funds have invested over $400 million in 13 companies from this sector.
Location:
Saint Petersburg, Russia
Years:
2016
Shareholding:
Minority stake

Solopharm is a producer of pharmaceuticals, with focus on liquid drugs production. Product portfolio of Solopharm includes infusions, injectables, and a number of emerging branded products — ophthalmological drugs, nasal forms. All the drugs are generic drugs. Products are sold both to Russian hospitals and to pharmacies. The Company operates modern production facility located in Saint-Petersburg.

Other projects

News

21 May 2019

Media Statement.

BVCP statement on the decision to deny Philippe Delpal’s appeal regarding the form of pre-trial detention.
17 May 2019

Media Statement.

BVCP statement on ruling by Amur Court of Arbitration.
06 May 2019

Media Statement.

BVCP statement regarding court refusal to change form of detention for Michael Calvey.
29 April 2019

Media Statement.

BVCP statement concerning the rejection of appeal against prolongation of the pre-trial detention.
11 April 2019

Media Statement.

Baring Vostok welcomes the decision to release Michael Calvey to house arrest.
10 April 2019

Media Statement.

BVCP statement regarding pre-trial detention of Ivan Zyuzin, Vagan Abgaryan and Maxim Vladimirov.
10 April 2019

Media Statement.

Baring Vostok welcomes the applications made by the Investigative Committee for Michael Calvey and Alexey Kordichev to be transferred to house arrest, and hopes that the court will give due consideration to the applications.